Cargando…

Decitabine-Induced Changes in Human Myelodysplastic Syndrome Cell Line SKM-1 Are Mediated by FOXO3A Activation

The epigenetic silencing of tumor suppressor genes in myelodysplastic syndromes (MDS) can potentially confer a growth advantage to individual cellular clones. Currently, the recommended treatment for patients with high-risk MDS is the methylation agent decitabine (DAC), a drug that can induce the re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Wen, Dai, Hanjun, Yan, Ming, Cai, Xiaojun, Luo, Hong, Ke, Min, Liu, Zeming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662805/ https://www.ncbi.nlm.nih.gov/pubmed/29124072 http://dx.doi.org/10.1155/2017/4302320

Ejemplares similares

Decitabine Induces Change of Biological Traits in Myelodysplastic Syndromes via FOXO1 Activation
por: Zhang, Zheng, et al.
Publicado: (2021)

Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM-1 human myelodysplastic syndrome cell line
por: Hua, Hai-Ying, et al.
Publicado: (2016)

Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562
por: Li, Nianyi, et al.
Publicado: (2017)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
por: Qin, Taichun, et al.
Publicado: (2011)

In Vitro Evaluation of Two Novel Antimalarial Derivatives of SKM13: SKM13-MeO and SKM13-F
por: Trinh, Thuy-Tien Thi, et al.
Publicado: (2022)

Spotlight on decitabine for myelodysplastic syndromes in Chinese patients
por: Jing, Yu, et al.
Publicado: (2015)

P739: INCREASED FOXO1 EXPRESSION IS ASSOCIATED WITH BETTER PROGNOSIS IN MYELODYSPLASTIC SYNDROME PATIENTS RECEIVING DECITABINE THERAPY
por: Zhang, Zheng, et al.
Publicado: (2023)

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
por: Garcia, Jacqueline S, et al.
Publicado: (2010)

Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes
por: DING, KAI, et al.
Publicado: (2016)

Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes
Publicado: (2022)

Anti-malarial activity of HCl salt of SKM13 (SKM13-2HCl)
por: Trinh, Thuy-Tien Thi, et al.
Publicado: (2022)

Clinical effect of decitabine in the treatment of myelodysplastic syndrome and influencing factors
por: Liu, Tangxia, et al.
Publicado: (2020)

Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study
por: Wu, Depei, et al.
Publicado: (2015)

Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis
por: Li, Xiao, et al.
Publicado: (2014)

Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
por: Ye, Xingnong, et al.
Publicado: (2017)

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes
por: Kim, Seungyoun, et al.
Publicado: (2021)

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
por: Yun, John Paul, et al.
Publicado: (2023)

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial
por: Liu, Hui, et al.
Publicado: (2023)

P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
por: Zeidan, Amer M., et al.
Publicado: (2023)

Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines
por: Cluzeau, Thomas, et al.
Publicado: (2014)

Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome
por: Jung, Hyun Ae, et al.
Publicado: (2021)

Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
por: Hu, Naibo, et al.
Publicado: (2021)

SkM‐ing information from traumatized tissue
por: Crispin, Philip J., et al.
Publicado: (2022)

Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS
por: Luo, Shuna, et al.
Publicado: (2020)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
por: Mandhan, Nikeeta, et al.
Publicado: (2021)

A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome
por: Jeong, Seong Hyun, et al.
Publicado: (2015)

A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
por: Almasri, Jehad, et al.
Publicado: (2018)

Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome
por: Han, Seunghoon, et al.
Publicado: (2015)

Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients
por: Jung, Hyun Ae, et al.
Publicado: (2015)

Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen
por: Saleh, Mostafa F. M., et al.
Publicado: (2017)

Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
por: Serin, Istemi, et al.
Publicado: (2020)

Statistical Machine-Learning Methods for Genomic Prediction Using the SKM Library
por: Montesinos López, Osval A., et al.
Publicado: (2023)

Decreased FOXO1 Expression Is Correlated with Poor Prognosis in Myelodysplastic Syndromes
por: Zhang, Zheng, et al.
Publicado: (2022)

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen
por: Ali, Alaa M., et al.
Publicado: (2017)

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Daver, Naval, et al.
Publicado: (2017)

Elevated TWIST1 expression in myelodysplastic syndromes/ acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine
por: Li, Hongjiao, et al.
Publicado: (2020)

Anti-fibrotic, anti-VEGF or radiotherapy treatments as adjuvants for pterygium excision: a systematic review and network meta-analysis
por: Zeng, Wen, et al.
Publicado: (2017)

Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis
por: Zhang, Jing, et al.
Publicado: (2015)

Toward Biological Pacing by Cellular Delivery of Hcn2/SkM1
por: Végh, Anna M. D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_koapf601acu0l0hi910bqmr8mt